Search results for " ERA"

showing 10 items of 156 documents

Der Zerfall des Schriftdeutschen im Estado Novo?

2017

Zusammenfassung Der folgende Beitrag beschäftigt sich mit Sprechern des Hunsrückischen in Brasilien und deren Gebrauch des Schriftdeutschen im 20. Jahrhundert. Basis der Analyse ist ein Korpus von Privatbriefen, die während der ersten Diktatur geschrieben wurden. Der Fokus der Analyse ist die Frage nach einer uniformen Schriftnorm für diese Sprechergruppe, deren Muttersprache fast ausschließlich mündlich verwendet wurde. Es wird argumentiert, dass der Estado Novo nicht die einzige Ursache für den Dachsprachenwechsel vom Deutschen zum Portugiesischen war, jedoch entscheidend dazu beigetragen hat, dass die Etablierung einer brasilianischen Schriftnorm des Deutschen endgültig verhindert wurde.…

media_common.quotation_subjectFirst languagedeutsche MinderheitenGermanLinguistic ContactSprachwandelminorias alemãsddc:430Brasilienddc:830General Environmental ScienceLanguage policymedia_commonhunsriqueanoBrasilEstado NovoVargas EraPortugiesischcontato linguísticoArtVariety (linguistics)language.human_languageLinguisticsSprachkontaktHunsrückischlanguageGeneral Earth and Planetary SciencesGerman MinoritiesPerformance artPortugueseHumanitiesBrazilPandaemonium Germanicum
researchProduct

Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements

2021

The World Health Organization (WHO) targets for eliminating HCV by 2030 may be overambitious for many high-income countries. Recent analyses (ie, data from 2017 to 2019) show that only 11 countries are on track for meeting WHO’s elimination targets. For a country to be truly on track, it is important that the majority of infected individuals be identified and treated. There is still a need for country and population-specific evaluations within the different HCV screening and treatment strategies available, in order to assess their cost-effectiveness and sustainability and support an evidence-based policy for HCV elimination. Any health policy model is affected by the diversity and quality o…

media_common.quotation_subjectWorld Health Organizationdisease burden03 medical and health sciences0302 clinical medicineOrder (exchange)PandemicHumansQuality (business)Disease EradicationSet (psychology)Disease burdenHealth policymedia_commonPublic economicsHepatologyHCV screeningHealth PolicymicroeliminationCOVID-19Hepatitis CWHO targetHCV elimination030220 oncology & carcinogenesisSustainability030211 gastroenterology & hepatologyBusinessHumanDiversity (politics)Liver International
researchProduct

What are the risk factors of failure of enhanced recovery after right colectomy? Results of a prospective study on 140 consecutive cases

2020

Purpose Nausea and vomiting is the main cause of failure of enhanced recovery protocol (ERP) after right hemicolectomy. Methods From January 2013 to January 2018, all patients undergoing right hemicolectomy were prospectively included. Patients undergoing emergency surgery, additional complex procedure or temporary stoma, nasogastric tube (NGT) maintenance, or abdominal drainage were excluded. Failure of ERP was defined as nausea/vomiting precluding oral feeding after POD3 and/or the occurrence of postoperative ileus requiring NGT and/or length of stay (LOS) ≥ 8 days except for patients awaiting admission in rehabilitation unit. Risk factors of failure of ERP were identified using univariat…

medicine.medical_specialtyAnemiaNauseaRight colectomy enhanced recovery ERAS perioperative care postoperative outcome colorectal surgery03 medical and health sciences0302 clinical medicineIleusPostoperative ComplicationsRisk FactorsmedicineHumansProspective StudiesProspective cohort studyContraindicationColectomybusiness.industryMortality rateGastroenterologyLength of Staymedicine.diseaseColorectal surgerySurgery030220 oncology & carcinogenesisRight ColectomyVomiting030211 gastroenterology & hepatologymedicine.symptombusiness
researchProduct

Current and future HCV therapy: do we still need other anti-HCV drugs?

2014

Eradication of hepatitis C virus (HCV) infection, at least in compensated patients, can help improve the outcomes of liver disease such as cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation, as well as perhaps extra-hepatic complications such as diabetes and cardiovascular risk. In the past few years, the landscape of antiviral therapy has evolved at a breathtaking pace from pegylated interferon (PEG-IFN) plus ribavirin (RBV) (PEG-IFN/RBV) to IFN-based strategies combining direct acting antivirals (DDAs) with PEG-IFN/RBV and finally IFN-free combinations of DAAs. In particular with these most recent developments, treatment regimens have become shorter, safer and even more e…

medicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationChronic hepatitis Cmedicine.disease_causeAntiviral AgentsLiver diseasechemistry.chemical_compoundPegylated interferonmedicineHumansDisease EradicationIntensive care medicineAntiviral AgentHepaciviruHepatologybusiness.industryMedicine (all)Ribavirinmedicine.diseaseHepatitis CClinical researchchemistryHepatocellular carcinomaImmunologyDrug Therapy CombinationDirect antiviral agentTherapybusinessHumanmedicine.drugLiver International
researchProduct

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe

2018

Abstract: Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically infected with a wide range of variation in prevalence across European Union countries. Although HCV continues to spread as a largely silent pandemic, its elimination is made possible through the availability of the new antiviral drugs and the implementation of prevention practices. On 17 February 2016, the Hepatitis B & C Public Policy Association held the first EU HCV Policy Summit in Brussels. This summit was an historic event as it was the first high-level conference focusing on the elimination of HCV at the European Union level. The …

medicine.medical_specialtyCivil societyEconomic growthMedizinPublic policyHepacivirusAntiviral AgentsPatient advocacy03 medical and health sciences0302 clinical medicineVirologyPolitical sciencePandemicPrevalencemedicineHumansmedia_common.cataloged_instanceEuropean Union030212 general & internal medicineDisease EradicationEuropean unionmedia_commongeographySummitgeography.geographical_feature_categoryHepatologyPublic healthmedicine.diseaseHepatitis CEuropeInfectious DiseasesHCVEpidemiological Monitoring030211 gastroenterology & hepatologyHuman medicineViral hepatitisJournal of Viral Hepatitis
researchProduct

Artificial intelligence: the unstoppable revolution in ophthalmology.

2020

Artificial Intelligence (AI) is an unstoppable force that is starting to permeate all aspects of our society as part of the revolution being brought into our lives (and into medicine) by the digital era, and accelerated by the current COVID-19 pandemic. As the population ages and developing countries move forward, AI-based systems may be a key asset in streamlining the screening, staging, and treatment planning of sight-threatening eye conditions, offloading the most tedious tasks from the experts, allowing for a greater population coverage, and bringing the best possible care to every patient. This paper presents a review of the state of the art of AI in the field of ophthalmology, focusin…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Digital eraComputer sciencePopulationAsset (computer security)Field (computer science)03 medical and health sciences0302 clinical medicineArtificial IntelligenceOphthalmologymedicineHumanseducationPandemicseducation.field_of_studybusiness.industrySARS-CoV-2Infant NewbornCOVID-19GlaucomaImage enhancementOphthalmology030221 ophthalmology & optometryArtificial intelligenceApplications of artificial intelligencebusiness030217 neurology & neurosurgeryStrengths and weaknessesSurvey of ophthalmology
researchProduct

Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register)

2021

Purpose: To evaluate clinical features, treatments, and outcomes of osteoporotic patients admitted to internal medicine and geriatric wards compared with non-osteoporotic patients (REPOSI registry). Methods: We studied 4714 patients hospitalized between 2010 and 2016. We reported age, sex, educational level, living status, comorbidities and drugs taken, Cumulative Illness Rating Scale (CIRS), Barthel Index, Short-Blessed Test, 4-item Geriatric Depression Scale, serum hemoglobin, creatinine, and clinical outcomes. Osteoporosis was defined based on the diagnoses recorded at admission, according to the following ICD9: 733, 805-813, 820-823. Results: Twelve percent of the patients had a preadmi…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosis030209 endocrinology & metabolismNO03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRating scaleInternal medicineDiabetes mellitusVitamin D and neurologyInternal MedicineMedicineeracturesHumansBisphosphonateMedical diagnosisbisphosphonates; eractures; osteoporosis; vitamin DVitamin DAgedCreatinineRehabilitationLS7_9Bisphosphonates; Fractures; Osteoporosis; Vitamin D.business.industryOsteoporosiBisphosphonatesmedicine.diseaseHospitalizationFracturechemistryItaly030220 oncology & carcinogenesisOsteoporosisGeriatric Depression ScaleVitamin D.businessBisphosphonates; Fractures; Osteoporosis; Vitamin D; Aged; Hospitalization; Humans; Internal Medicine; Italy; Vitamin D; OsteoporosisBisphosphonates; Fractures; Osteoporosis; Vitamin DFractures
researchProduct

Is global elimination of HCV realistic?

2017

The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. The goal of the World Health Organization (WHO) is to reduce the incidence of chronic hepatitis infection from the current 6-10 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of HCV infection, screening and testing practices and strategies to link HCV patients to care. This review will focus on the current state of …

medicine.medical_specialtySustained Virologic ResponseHepatitis C virusCost-Benefit Analysismedicine.disease_causeGlobal HealthWorld Health OrganizationAntiviral AgentsWorld health03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansMass Screening030212 general & internal medicineDisease EradicationIntensive care medicineSubstance Abuse Intravenouslinkage to caredirect antiviral agentHepatologybusiness.industryscreeningIncidence (epidemiology)Hcv clearancevirus diseasesHepatologyPatient Acceptance of Health CareHepatitis Cdigestive system diseases030211 gastroenterology & hepatologybusinessPatient awarenessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

El programa Erasmus y el desarrollo de capacidades : un análisis multidimensional

2014

Presentamos un proyecto de investigación cuyo objeto de estudio es la experiencia Erasmus, teniendo como protagonistas a aquellas personas que participan en el mismo, las que lo gestionan y promueven y a aquellos que se interesan por los beneficios de dicha iniciativa. En líneas generales, nos mueve el propósito de obtener información sobre las aportaciones del programa respecto al desarrollo humano a partir del enfoque de capacidades de Amartya Sen y Marta Nussbaum. Nuestra finalidad última se concreta, por tanto, en la siguiente cuestión: ¿Cómo contribuye el programa Erasmus a dicho desarrollo? Esto nos ha llevado a establecer tres grandes procesos. En primer lugar, hacemos una revisión d…

programa ERASMUSdesarrollo humanoenfoque de capacidades:PEDAGOGÍA [UNESCO]investigación cualitativaUNESCO::PEDAGOGÍA
researchProduct

Els reptes de les publicacions científiques espanyoles en el desenvolupament de l'Europa del coneixement

2010

Les publicacions científiques s’estan veient afectades per les transformacions que s’han produit en l’última dècada a partir de la creació del EEES y EEI. Un dels objectius prioritaris de la Unió Europea és aconseguir una Europa del coneixement vertebrada per l’activitat universitària. En aquest context, les publicacions científiques juguen un paper destacat com exponent de la producció científica i mitjà autoritzat de difusió. No obstant, l’activitat científica europea mesurada mitjançant les publicacions especialitzades no arriba als nivells en què es troben els seus competidors més directes, Estats Units i Japó (principalment en biomedicina i ciències de les materials, respectivament).

publicaciones cinetíficas; EEES; EEI; universidadpublicaciones cinetíficasEEIEEESscientific journals EHEA ERA quality criteria reaserch and innovation (R&I)lcsh:Llcsh:L7-991lcsh:Education (General)lcsh:Educationuniversidad
researchProduct